<DOC>
	<DOCNO>NCT02139306</DOCNO>
	<brief_summary>This Phase 3 , international , multicenter , randomize , double-blind , placebo-controlled , efficacy safety study ataluren patient nonsense mutation cystic fibrosis ( nmCF ) receive chronic inhaled aminoglycosides .</brief_summary>
	<brief_title>Study Ataluren Nonsense Mutation Cystic Fibrosis ( ACT CF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Evidence sign date informed consent/assent document ( ) indicate subject ( and/or parent/legal guardian ) inform pertinent aspect trial Age &gt; =6 year . Body weight &gt; =16 kg . Sweat chloride &gt; 60 mEq/L Documentation presence nonsense mutation least 1 allele CFTR gene , determine genotyping perform laboratory certified College American Pathologists ( CAP ) , Clinical Laboratory Improvement Act/Amendment ( CLIA ) , equivalent organization Verification blood sample drawn sequence CFTR gene Ability perform valid , reproducible spirometry test use studyspecific spirometer demonstration FEV1 &gt; =40 % &lt; =90 % predict Demonstration Visit 2 valid % predict FEV1 within 15 % Screening % predict FEV1 value Resting oxygen saturation ( measure pulse oximetry ) &gt; =92 % room air . Confirmed screen laboratory value within prespecified range In subject sexually active , willingness abstain sexual intercourse employ barrier medical method contraception study drug administration 60day followup period Willingness ability comply study procedures assessment , include schedule visit , drug administration plan , study procedure , laboratory test , study restriction Known hypersensitivity ingredient excipients study drug Previous participation Phase 3 trial ataluren ( PTC124GD009CF ) . Any change ( initiation , change type drug , dose modification , schedule modification , interruption , discontinuation , reinitiation ) chronic treatment/prophylaxis regimen CF CFrelated condition within 4 week prior screen Chronic use inhale aminoglycosides ( eg , tobramycin ) use inhale aminoglycosides within 4 month prior screen . Exposure another investigational drug within 4 week prior screen Ongoing participation therapeutic clinical trial Evidence pulmonary exacerbation acute upper low respiratory tract infection ( include viral illness ) within 3 week prior screen Treatment intravenous antibiotic within 3 week prior screen Ongoing immunosuppressive therapy ( corticosteroid ) Ongoing warfarin , phenytoin , tolbutamide therapy History solid organ hematological transplantation Major complication lung disease ( include massive hemoptysis , pneumothorax , pleural effusion ) within 8 week prior screen Known portal hypertension Positive hepatitis B surface antigen , hepatitis C antibody test , human immunodeficiency virus ( HIV ) test Pregnancy breastfeed Current smoker smoke history &gt; =10 packyears ( number cigarette packs/day x number year smoke ) . Prior ongoing medical condition ( eg , concomitant illness , alcoholism , drug abuse , psychiatric condition ) , medical history , physical finding , ECG finding , laboratory abnormality , investigator 's opinion , could adversely affect safety subject , make unlikely course treatment followup would complete , could impair assessment study result</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>